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ABSTRACT
Since the outbreak of COVID-19 in China in December 
2019, a pandemic has rapidly developed on a scale 
that has overwhelmed health services in a number of 
countries. COVID-19 has the potential to lead to severe 
hypoxia; this is usually the cause of death if it occurs. 
In a substantial number of patients, adequate arterial 
oxygenation cannot be achieved with supplementary 
oxygen therapy alone. To date, there has been no clear 
guideline endorsement of ward- based non- invasive 
pressure support (NIPS) for severely hypoxic patients 
who are deemed unlikely to benefit from invasive 
ventilation. We established a ward- based NIPS service 
for COVID-19 PCR- positive patients, with severe hypoxia, 
and in whom escalation to critical care for invasive 
ventilation was not deemed appropriate. A retrospective 
analysis of survival in these patients was undertaken. 
Twenty- eight patients were included. Ward- based 
NIPS for severe hypoxia was associated with a 50% 
survival in this cohort. This compares favourably with 
Intensive Care National Audit and Research Centre 
survival data following invasive ventilation in a less frail, 
less comorbid and younger population. These results 
suggest that ward- based NIPS should be considered as 
a treatment option in an integrated escalation strategy 
in all units managing respiratory failure secondary to 
COVID-19.
INTRODUCTION
COVID-19 is a new disease caused by severe 
acute respiratory syndrome coronavirus 2 
(SARS- CoV-2). The basic pathophysiology 
of this disease is not yet understood, and 
optimal management is not yet known. Since 
the outbreak in China in December 2019, a 
pandemic has rapidly developed with the 
scale of the outbreak overwhelming health 
services in many countries. While trials of 
disease specific treatments are underway, 
to date, there is no pharmaceutical agent 
with proven efficacy, and hospital manage-
ment is essentially supportive. COVID-19 
is known to involve several organs but its 
effect on the lungs, with impairment of gas 
transfer and severe hypoxia, is usually the 
cause of death when it occurs. In a substantial 
number of patients, adequate arterial oxygen-
ation cannot be achieved with supplemental 
oxygen alone.
To date, non- invasive pressure support 
(NIPS) has been regarded as a suboptimal 
alternative to invasive ventilation in severely 
hypoxic patients with COVID-19. There 
has been no clear guideline endorsement 
of NIPS as part of an integrated respira-
tory escalation strategy1–4; as a result, the 
establishment of COVID-19 NIPS units has 
not been prioritised. In severely hypoxic 
patients deemed unsuitable for invasive 
ventilation, some hospitals have been able 
to offer nothing more than supplemental 
oxygen and palliation.
METHODS
At the start of the COVID-19 crisis in the UK, 
we set up a ward- based unit (physiotherapy 
delivered) for non- invasive respiratory 
support. Appropriateness for escalation to 
ICU was based on the NICE rapid guideline.5 
Frailty was assessed using the Rockwood clin-
ical frailty score, first published in 2005 and 
incorporated in the NICE rapid guidance for 
COVID-19 escalation.5 6 NIPS was offered to 
patients believed to be too frail to have the 
potential to benefit from invasive ventilation. 
Referral to the non- invasive support unit was 
in accordance with the escalation algorithm 
shown in figure 1.
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In patients for whom an oxygen saturation of ≥94% 
could not be achieved with <40% supplemental oxygen 
(via Venturi), Continuous Positive Airway Pressure 
(CPAP), (or Bilevel Positive Airway Pressure (BiPAP) 
in five patients with a history of ventilatory failure) was 
offered. Positive airways pressure (10– 14 cmH2O) with 
entrained oxygen flow rates to a maximum of 15 L/
min was used. Pressure was limited, to some degree, by 
patient comfort. Pressure and flow rates were otherwise 
titrated to achieve oxygen saturation of ≥94%. Patients 
had breaks in treatment for meals during which time 
they were supported by high flow oxygen via a face 
mask. If tolerance precluded continuation of treat-
ment, patients were switched to high flow oxygen via 
a non- rebreathe circuit to achieve the best possible 
oxygen saturation. Such de- escalation in treatment 
did not preclude re- escalation if the patient consented 
and if oxygenation warranted it. Weaning from CPAP 
was considered when oxygen saturation during breaks 
from treatment indicated that supplemental oxygen 
might be sufficient. Unlike traditional management of 
acute ventilatory failure with BiPAP, prolonged gradual 
weaning was not needed. Almost all of our patients 
with COVID-19 displayed strong respiratory drive, 
with low or low/normal arterial partial pressure of 
Carbon Dioxide (PaCO2)on admission Arterial Blood 
Gas (ABG). Some patients however needed CPAP over-
night for a further 24–48 hours after daytime weaning. 
All patients included tested positive for SARS- CoV-2 
infection.
Imaging included both chest radiograph (CXR) 
and CT results and is reported as the most recent 
imaging prior to commencement of NIPS. Imaging 
appearances were defined as per the British Society 
of Thoracic Imaging recommendations (available 
at: https://www. bsti. org. uk/ covid- 19- resources/ 
covid- 19- bsti- reporting- templates).
Figure 1 Respiratory support escalation stratgey in acute presentation of COVID-19. CPAP, Continuous Positive Airways 
Pressure; COPD, Chronic Obstructive Pulmonary Disease; NIV, Non- Invasive Ventilation; ITU, Intensive Therapy Unit
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Caldicott approval was obtained for the establishment 
of a database of our patients. Data collected included age, 
gender, clinical frailty score, comorbidities, acute clinical 
findings and the dichotomous outcome of discharge or 
death. We retrospectively reviewed our outcome data for 
all patients who had achieved an outcome between 23 
March 2020 and 22 April 2020. Patients were excluded 
from the analysis if they had been deemed appropriate 
for escalation to invasive ventilation.
RESULTS
Over the time period, 136 patients were admitted to 
non- respiratory COVID-19 wards, 44 to the intensive 
care unit and 47 to respiratory COVID-19 wards. Thir-
ty- two patients admitted to the respiratory COVID-19 
wards were treated with NIPS. Of these, four patients 
(who survived) were excluded from the analysis as 
they were deemed appropriate for invasive ventilation. 
Analysis was performed on the remaining 28 patients. 
Fifteen (54%) were male, median age was 81.5 years 
(range 54–91) and 21 (75%) were Caucasian. The 
majority of patients (82.1%) were admitted from their 
own home. Median (IQR) clinical frailty score was 5 
(4–6). Twenty- six patients had CXR only, with two 
patients additionally undergoing chest CT. Comorbid-
ities, radiology and other physiological parameters are 
shown in table 1. Twenty- three patients received CPAP, 
while five patients, with a history of ventilatory failure, 
received BiPAP. Median duration of treatment with 
NIPS was 5 days (range 1–14) in patients discharged 
and 3 days (1–13) in those who died. Fourteen (50%) 
of patients survived to discharge. Individual patient 
characteristics and outcome are shown in table 2. In 
patients who died, 13 of 14 had a documented certifi-
cate of medical cause of death. Of these, ‘COIVID-19’ 
was recorded as the primary cause of death in all of 
cases.
There were no statistically significant differences 
found between age, frailty score, admission from home, 
nor prevalence of any comorbidity between those that 
survived and did not survive. Additionally, there were 
no statistically significant differences between SpO2 at 
point of deterioration, presence of acute kidney injury, 
presence of acute derangement in liver function tests 
nor ventilatory pressures. The only statistically signifi-
cant difference between survivors and non- survivors was 
the presence of ‘classical’ imaging appearances (Survi-
vors ‘classical’ imaging=35.7% vs non- survivors ‘classical’ 
imaging=78.6%; χ2 p=0.034).
DISCUSSION
At outset, expectations of survival were not high. Inten-
sive Care National Audit and Research Centre (ICNARC) 
data on survival in a COVID-19 cohort managed with inva-
sive ventilation who were generally younger (median age 
63 years) and less frail (91.3% had CFS<4), with a substan-
tially lower comorbidity burden than our population, 
indicated a survival rate of only 33%.7 Contemporaneous 
data from our institution suggests a survival of 50% in 
patients who were intubated and mechanically ventilated.
NIPS is known to offer additional support to gas 
exchange beyond high flow oxygen. These limited data 
suggest that NIPS outcomes may compare favourably 
with those of intubated patients. What is particularly 
surprising about these data is that, in a population 
Table 1 Population demographics and treatment 
parameters
Variable Study population
n 28
Comorbidities
  Hypertension (%) 22 (78.6)
  Ischaemic heart disease (%) 10 (35.7)
  Atrial fibrillation (%) 8 (28.6)
  Congestive cardiac failure (%)
  If yes, NYHA class (IQR)
7 (25.0)
3 (1–3)
  Diabetes mellitus (%) 15 (53.6)
  Chronic kidney disease (%)
  If yes, stage (IQR)
15 (53.6)
3b (3a–3b)
  COPD (%) 5 (17.9)
  Bronchiectasis (%) 1 (3.6)
  Asthma (%) 6 (21.4)
  Active malignancy (%) 3 (10.7)
  Dementia (%) 1 (3.6)
  Stroke (%) 2 (7.1)
  Previous pulmonary or venous 
thromboembolism (%)
2 (7.1)
Results from the acute admission
  Imaging ‘Classical’ (%) 16 (57.1)
  Imaging ‘Indeterminate’ (%) 8 (28.6)
  SpO2 prior to NIPS (IQR) 89% (85–92.75)
  Acute kidney injury (%) 9 (32.1)
  Acutely deranged liver function tests 
(%)
4 (14.3)
  NIPS parameters
  Received CPAP (%) 23 (82.1)
  Received BiPAP (%) 5 (17.9)
  CPAP max pressure cmH2O (SD) 12.7 (2.1)
  BiPAP maximum inspiratory pressure 
cmH2O (SD)
22.4 (6.0)
  BiPAP maximum expiratory pressure 
cmH2O (SD)
10.2 (2.9)
  BiPAP max back up rate (SD) 13.2 (1.8)
Data are presented as mean (SD) where parametric, median (IQR) 
where non- parametric, or absolute number (%) where categorical.
BiPAP, Bi- level Positive Airway Pressure ; COPD, Chronic 
Obstructive Pulmonary Disease; CPAP, Continuous Positive Airway 
Pressure; NHYA, New York Heart Association; NIPS, non- invasive 
pressure support; SpO2, Peripheral Oxygen Saturation.
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with poor physiological reserve, who were not deemed 
appropriate for escalation to intensive care, survival 
rate appears to be better than that reported by ICNARC 
and at least equivalent to survival in intubated patients 
within our own institution.7 No conclusion on the rela-
tive merits of the two treatments can be drawn on such a 
small data set; however, NIPS, in particular the manner 
in which it is delivered, enjoys a significant physio-
logical advantage over invasive ventilation that neces-
sitates sedation. The unconscious ventilated patient 
is managed either supine or prone. Compared with 
upright posture, both positions are disadvantageous 
for ventilation- perfusion (V/Q) matching within the 
lungs and significantly compromises gas exchange. The 
upright position in these non- sedated patients on NIPS 
is optimal for V/Q matching. It uses the effect of gravity 
on lung perfusion, matching it with the differential 
effects on ventilation within the lung resulting from 
diaphragmatic excursion. Better V/Q matching implies 
better gas exchange.
CONCLUSION
These data support treatment with NIPS (CPAP or BiPAP) 
as part of a respiratory escalation strategy in hospitals 
managing COVID-19 and in accordance with the algo-
rithm shown in figure 1.
A larger study is urgently needed to determine if 
there is an advantage to managing patients on NIPS (in 
the upright position) over invasive ventilation, which 
precludes optimal positioning for V/Q matching.
At the time of writing, bed occupancy rates are declining 
in Europe, but further waves of infection are inevitable 
as social distancing restrictions are relaxed. NIPS clearly 
Table 2 Individual patient demographics and outcome
Decade of 
life Gender Clinical frailty score BiPAP/CPAP Duration of respiratory support (days) Outcome
80s M 2 BiPAP 5 Death
80s M 5 CPAP* 5 Death
90s M 4 CPAP 0 Death
90s F 6 CPAP 3 Death
70s M 6 CPAP 1 Death
80s F 4 CPAP 13 Death
90s M 6 CPAP* 1 Death
70s M 7 CPAP 3 Death
80s F 3 CPAP* 3 Death
70s M 5 BiPAP* 9 Death
80s F 6 CPAP 2 Death
90s F 6 CPAP 1 Death
80s M 7 CPAP 1 Death
80s M 2 CPAP 8 Death
80s F 5 CPAP 5 Discharge
50s F 6 BiPAP 4 Discharge
80s F 4 BiPAP 14 Discharge
70s M 4 CPAP 3 Discharge
60s M 5 CPAP 5 Discharge
70s M 4 CPAP 5 Discharge
70s M 7 BiPAP 4 Discharge
80s F 3 CPAP 8 Discharge
90s M 5 CPAP 6 Discharge
60s F 7 CPAP 5 Discharge
80s M 3 CPAP 7 Discharge
70s F 4 CPAP 14 Discharge
80s F 5 CPAP 3 Discharge
80s F 5 CPAP 5 Discharge
*Poorly tolerated respiratory support, trialled but not maintained on optimum setting.
BiPAP, Bi- level Positive Airway Pressure; CPAP, Continuous Positive Airway Pressure.
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has a place in the management of the severely hypoxic 
patient with COVID-19. It may improve overall survival 
rates and ease pressure on the more resource intense 
ICU environment. It should be considered in ongoing 
resource planning in any healthcare system.
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